Market Movers: GRML, QFIN, ADBT, and SYRE Fall

Greenland Mines Ltd. (NASDAQ: GRML) led the decline, with its stock falling 48.09% to $5.04. The drop followed the company’s proposed $20 million public offering, which raised concerns about dilution for existing shareholders.

Qfin Holdings, Inc. (NASDAQ: QFIN) fell 18.91% to $9.35 after its second-quarter results showed pressure on the business. The company beat earnings expectations, but revenue missed estimates and fell 31.6% year-over-year, reflecting weaker loan demand and tighter risk controls. Non-GAAP net profit also declined sharply from the prior quarter.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) also fell 12.81% to $93.61 after releasing topline results from the rheumatoid arthritis sub-study of its SKYWAY Phase 2 trial evaluating SPY072. The data disappointed investors, although some analysts noted that Spyre’s main strategic focus remains inflammatory bowel disease.

Several stocks declined sharply, with Greenland Mines Ltd. (GRML) plunging nearly 50% after announcing a proposed $20 million public offering that raised dilution concerns. Qfin Holdings (QFIN) dropped almost 19% following weaker Q2 revenue and sharply lower profit, while Spyre Therapeutics (SYRE) fell over 12% after disappointing rheumatoid arthritis trial results.